A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Inclusion Criteria:
Exclusion Criteria:
Newport Beach, California 92660, United States
Colorado Springs, Colorado 80907, United States
St. Petersburg, Florida 33709-3113, United States
West Palm Beach, Florida 33407-3209, United States
Savannah, Georgia 31406-2758, United States
Ann Arbor, Michigan 48104-5131, United States
Golden Valley, Minnesota 55422-4215, United States
Philadelphia, Pennsylvania 19107, United States
Newport News, Virginia 23606, United States
Virginia Beach, Virginia 23456-0019, United States